Search results for "Lupu"

showing 10 items of 216 documents

Howl variation across Himalayan, North African, Indian, and Holarctic wolf clades: tracing divergence in the world’s oldest wolf lineages using acous…

2017

Abstract Vocal divergence within species often corresponds to morphological, environmental, and genetic differences between populations. Wolf howls are long-range signals that encode individual, group, and subspecies differences, yet the factors that may drive this variation are poorly understood. Furthermore, the taxonomic division within the Canis genus remains contended and additional data are required to clarify the position of the Himalayan, North African, and Indian wolves within Canis lupus. We recorded 451 howls from the 3 most basal wolf lineages—Himalayan C. lupus chanco—Himalayan haplotype, North African C. lupus lupaster, and Indian C. lupus pallipes wolves—and present a howl ac…

0106 biological sciences0301 basic medicineHimalayan wolfbiologyArticlesSubspeciesacoustic variationgeographic variationbiology.organism_classification010603 evolutionary biology01 natural sciencesCanis lupusIndian wolfGenetic divergence03 medical and health sciences030104 developmental biologyHolarcticCanismammal communication.GenusEvolutionary biologySpecial Column: Communication cooperation and cognition in predatorsAnimal Science and ZoologyCladeCurrent Zoology
researchProduct

Urinary levels of sirtuin-1 associated with disease activity in lupus nephritis.

2017

Identifying new markers of disease flares in lupus nephritis (LN) that facilitate patient stratification and prognosis is important. Therefore, the aim of the present study was to analyze whether urinary SIRT1 expression was altered in LN and whether SIRT1 values in urine could be valuable biomarker of disease activity. In a cohort study, urinary pellets from 40 patients diagnosed with systemic lupus erythematosus (SLE) were analyzed. Clinical measures of lupus activity were assessed. The expression of SIRT1 was quantified by quantitative PCR (qRT-PCR) and immunoblot, then compared between patients with active lupus nephritis, in remission and healthy controls. Association with lupus activi…

0301 basic medicineAdultMalemedicine.medical_specialtyUrinary systemLupus nephritisGene ExpressionDiseaseUrineKidneyGastroenterologySeverity of Illness IndexPathogenesisCohort Studies03 medical and health sciencesSirtuin 1Internal medicinemedicineHumansLupus Erythematosus Systemicskin and connective tissue diseasesAgedSystemic lupus erythematosusbusiness.industryGeneral MedicineMiddle Agedmedicine.diseasePrognosisLupus Nephritis030104 developmental biologyReal-time polymerase chain reactionBiomarker (medicine)FemalebusinessBiomarkersClinical science (London, England : 1979)
researchProduct

Spleen tyrosine kinase (SYK) is a potential target for the treatment of cutaneous lupus erythematosus patients

2016

Spleen tyrosine kinase (SYK) is a protein kinase involved in cell proliferation and the regulation of inflammatory pathways. Due to the increasing evidence that kinase inhibitors have potential as specific anti-inflammatory drugs, we have investigated the potential for SYK inhibition as a therapeutic target in autoimmune diseases, particularly cutaneous lupus erythematosus (CLE). Skin samples of patients with different CLE subtypes and appropriate controls were analysed for the expression of SYK and SYK-associated pro-inflammatory mediators via gene expression analysis and immunohistochemistry. The functional role of SYK in keratinocytes was investigated in vitro, using LE-typical pro-infla…

0301 basic medicineCell typeSykchemical and pharmacologic phenomenaDermatologyenvironment and public healthBiochemistry03 medical and health sciencesImmune systemDownregulation and upregulationLupus Erythematosus CutaneousmedicineHumansSyk KinasePhosphorylationMolecular BiologyCells CulturedInnate immune systemSystemic lupus erythematosusKinasebusiness.industryhemic and immune systemsmedicine.diseaseenzymes and coenzymes (carbohydrates)030104 developmental biologyCase-Control StudiesImmunologyCytokinesPhosphorylationbiological phenomena cell phenomena and immunitybusinessExperimental Dermatology
researchProduct

Advances in the treatment of cutaneous lupus erythematosus.

2016

Lupus erythematosus (LE) is a multifactorial autoimmune disease with clinical manifestations of differing severity which may present with skin manifestations as primary sign of the disease (cutaneous lupus erythematosus, CLE) or as part of a disease spectrum (systemic lupus erythematosus, SLE). To date, no drugs are approved specifically for the treatment of CLE and only single agents have been applied in randomized controlled trials. Therefore, topical and systemic agents are used “off-label”, primarily based on open-label studies, case series, retrospective analyses, and expert opinions. In contrast, several agents, such as hydroxychloroquine, chloroquine, cyclophosphamide, azathioprine,…

0301 basic medicineCyclophosphamideDiscoid lupus erythematosusAzathioprineAntibodiesEtanerceptPolyethylene Glycols03 medical and health sciencesLupus Erythematosus DiscoidRheumatologyimmune system diseasesChloroquineMedicineHumansLupus Erythematosus SystemicMolecular Targeted TherapyPrecision Medicineskin and connective tissue diseasesRandomized Controlled Trials as TopicB-LymphocytesLupus erythematosusbusiness.industryInterleukin-6Anti-Inflammatory Agents Non-SteroidalHydroxychloroquinemedicine.diseaseBelimumab030104 developmental biologyImmunologyInterferonsbusinessBiomarkersAnti-SSA/Ro autoantibodiesmedicine.drugSignal TransductionLupus
researchProduct

Towards patient stratification and treatment in the autoimmune disease lupus erythematosus using a systems pharmacology approach

2015

Drug development in Systemic Lupus Erythematosus (SLE) has been hindered by poor translation from successful preclinical experiments to clinical efficacy. This lack of success has been attributed to the high heterogeneity of SLE patients and to the lack of understanding of disease physiopathology. Modelling approaches could be useful for supporting the identification of targets, biomarkers and patient subpopulations with differential response to drugs. However, the use of traditional quantitative models based on differential equations is not justifiable in a sparse data situation. Boolean networks models are less demanding on the required data to be implemented and can provide insights into…

0301 basic medicineDrugSystems biologymedia_common.quotation_subjectPharmaceutical ScienceAntineoplastic AgentsDiseaseBioinformaticsAutoimmune Diseases03 medical and health sciencesmedicineAnimalsCluster AnalysisHumansLupus Erythematosus SystemicComputer Simulationmedia_commonAutoimmune diseaseLupus erythematosusbusiness.industrySystems Biologymedicine.diseaseTreatment Outcome030104 developmental biologyDrug developmentPharmacology ClinicalbusinessBiological networkSystems pharmacologyEuropean Journal of Pharmaceutical Sciences
researchProduct

Guidelines for biomarkers in autoimmune rheumatic diseases - evidence based analysis

2018

Autoimmune rheumatic diseases are characterised by an abnormal immune system response, complement activation, cytokines dysregulation and inflammation. In last years, despite many progresses in managing these patients, it has been shown that clinical remission is reached in less than 50% of patients and a personalised and tailored therapeutic approach is still lacking resulting in a significant gap between guidelines and real-world practice. In this context, the need for biomarkers facilitating early diagnosis and profiling those individuals at the highest risk for a poor outcome has become of crucial interest. A biomarker generally refers to a measured characteristic which may be used as a…

0301 basic medicineEvidence-based practiceImmunologyInflammationGuidelines as TopicSystemic lupus erythematosuBioinformaticsAntiphospholipid syndrome; Biomarker; Rheumatoid arthritis; Sjögren syndrome; Spondyloarthritides; Systemic lupus erythematosus; Systemic sclerosis;Autoimmune DiseaseAutoimmune DiseasesRheumatic Disease03 medical and health sciencesTherapeutic approachSystemic sclerosiEconomica0302 clinical medicineImmune systemSystemic lupus erythematosusAntiphospholipid syndromeEarly DiagnosiRheumatic DiseasesAntiphospholipid syndromemedicineImmunology and AllergyHumansRheumatoid arthritisRheumatoid arthritiAntiphospholipid syndrome; Biomarker; Rheumatoid arthritis; Sjögren syndrome; Spondyloarthritides; Systemic lupus erythematosus; Systemic sclerosis030203 arthritis & rheumatologySpondyloarthritidebusiness.industryBiomarkermedicine.diseaseClinical diseaseSjögren syndromeAntiphospholipid syndrome; Biomarker; Rheumatoid arthritis; Sjögren syndrome; Spondyloarthritides; Systemic lupus erythematosus; Systemic sclerosis; Autoimmune Diseases; Biomarkers; Early Diagnosis; Evidence-Based Practice; Guidelines as Topic; Humans; Rheumatic Diseases; Immunology and Allergy; ImmunologySettore MED/16 - Reumatologia030104 developmental biologyEarly DiagnosisRheumatoid arthritisEvidence-Based PracticeBiomarker (medicine)SpondyloarthritidesSystemic sclerosismedicine.symptombusinessBiomarkersHuman
researchProduct

Immunomodulatory activity of Humulus lupulus bitter acids fraction: Enhancement of natural killer cells function by NKp44 activating receptor stimula…

2019

Abstract Humulus lupulus (Hop) contains numerous metabolites with anticancer potential. Despite this, their immunomodulatory activity, and in particular of bitter acids, is unknown. In this study, we demonstrated that a Hop pellet extract fraction containing bitter acids possesses immunomodulatory activity by enhancing Natural Killer (NK) cells function. After fractionation by semi-preparative Liquid Chromatography, three different fractions were obtained. The phytocomplex and the fractions were tested to verify the ability to modulate the NK compartment. Cytofluorimetric analysis revealed that a fraction containing bitter acids was able to up-regulate of NKG2D and NKp44 activating receptor…

0301 basic medicineHumulus lupulusBitter-acidsBitter-acids; Humulus lupulus; Immunomodulation; Natural killer cells; NutraceuticalsNatural killer cellMedicine (miscellaneous)StimulationHop (networking)Immunomodulation03 medical and health sciences0404 agricultural biotechnologyHumulus lupuluTX341-641ReceptorHumulus lupulus030109 nutrition & dieteticsNutrition and DieteticsbiologyChemistryNutrition. Foods and food supplyfood and beverages04 agricultural and veterinary sciencesbiology.organism_classificationNKG2D040401 food scienceCytolysisBiochemistryCell cultureBitter-acidNatural killer cellsNutraceuticalsBitter-acids Humulus lupulus Immunomodulation Natural killer cells NutraceuticalsFood ScienceK562 cellsJournal of Functional Foods
researchProduct

Cultivation trials of hop (Humulus lupulus L.) in semi-arid environments

2020

Abstract The recent developments in the market and craft beer industry in Italy have led to an increasing demand for local raw materials, such as barley malt and hops. Few works have been addressed to evaluate suitability and productivity of hop in semi-arid Italian environments. With this purpose, two experiments were carried out in 2018 and 2019, testing the suitability to cultivation of three commonly used hop varieties (Cascade, Chinook and Nuggett) in two typical semi-arid environments in Sicily. Phenological stages were also evaluated, and GDDs accumulated in vegetative and reproductive stages were calculated according to 9 different methods, dealing with three Tbase temperatures (0 °…

0301 basic medicineHumulus lupulusThermal sumsOrganolepticCraft beerSensory analysisHop (networking)Crop03 medical and health sciences0302 clinical medicineYield (wine)lcsh:Social sciences (General)lcsh:Science (General)MathematicsMultidisciplinarybiologyPhenologyCrop yieldDevelopment stagesMediterranean agro-ecosystemsbiology.organism_classificationAgronomySettore AGR/02 - Agronomia E Coltivazioni ErbaceeHorticulture030104 developmental biologyAgricultural sciencelcsh:H1-99Craft beer Mediterranean agro-ecosystems Thermal sums Development stages Agricultural science Agronomy Crop production Crop quality Crop yields030217 neurology & neurosurgerylcsh:Q1-390Heliyon
researchProduct

Screening of herbal extracts for TLR2- and TLR4-dependent anti-inflammatory effects.

2018

Herbal extracts represent an ample source of natural compounds, with potential to be used in improving human health. There is a growing interest in using natural extracts as possible new treatment strategies for inflammatory diseases. We therefore aimed at identifying herbal extracts that affect inflammatory signaling pathways through toll-like receptors (TLRs), TLR2 and TLR4. Ninety-nine ethanolic extracts were screened in THP-1 monocytes and HeLa-TLR4 transfected reporter cells for their effects on stimulated TLR2 and TLR4 signaling pathways. The 28 identified anti-inflammatory extracts were tested in comparative assays of stimulated HEK-TLR2 and HEK-TLR4 transfected reporter cells to dif…

0301 basic medicineLeavesHumulus lupulusTHP-1 CellsPhysiologymedicine.medical_treatmentAnti-Inflammatory AgentsDrug Evaluation Preclinicallcsh:MedicinePlant SciencePharmacologyPlant RootsImmune ReceptorsBiochemistryMonocytesWhite Blood CellsCell SignalingAnimal CellsImmune PhysiologyMedicine and Health SciencesMembrane Receptor Signalinglcsh:ScienceToll-like ReceptorsFlowering PlantsInnate Immune SystemMultidisciplinaryImmune System ProteinsbiologyOrganic CompoundsPlant AnatomyEukaryotaPlantsImmune Receptor SignalingChemistryCytokinevisual_artPhysical Sciencesvisual_art.visual_art_mediumPlant BarkCytokinesBarkSignal transductionCellular TypesResearch ArticleSignal Transductionmedicine.drug_classImmune CellsImmunologyTransfectionAnti-inflammatory03 medical and health sciencesmedicineHumansBlood CellsEthanolPlant ExtractsMacrophagesCinnamomum verumlcsh:ROrganic ChemistryOrganismsChemical CompoundsBiology and Life SciencesProteinsCell BiologyMolecular Developmentbiology.organism_classificationToll-Like Receptor 2Plant LeavesToll-Like Receptor 4TLR2030104 developmental biologyHEK293 CellsGene Expression RegulationCell cultureAlcoholsImmune Systemlcsh:QHeLa CellsDevelopmental BiologyPloS one
researchProduct

Plasmacytoid dendritic cells promote systemic sclerosis with a key role for TLR8

2018

Systemic sclerosis (SSc) is a multisystem life-threatening fibrosing disorder that lacks effective treatment. The link between the inflammation observed in organs such as the skin and profibrotic mechanisms is not well understood. The plasmacytoid dendritic cell (pDC) is a key cell type mediating Toll-like receptor (TLR)-induced inflammation in autoimmune disease patients, including lupus and skin diseases with interface dermatitis. However, the role of pDCs in fibrosis is less clear. We show that pDCs infiltrate the skin of SSc patients and are chronically activated, leading to secretion of interferon-α (IFN-α) and CXCL4, which are both hallmarks of the disease. We demonstrate that the s…

0301 basic medicineMaleInflammationPlasmacytoid dendritic cellPlatelet Factor 4SclerodermaArticlePathogenesis03 medical and health sciencesBleomycinMice0302 clinical medicineFibrosismedicineAnimalsHumansSkin030203 arthritis & rheumatologyAutoimmune diseaseSystemic lupus erythematosusScleroderma Systemicintegumentary systembusiness.industryMedicine (all)Interferon-alphahemic and immune systemsGeneral MedicineTLR7Dendritic CellsMiddle Agedmedicine.diseaseFibrosisDisease Models Animal030104 developmental biologyToll-Like Receptor 7Toll-Like Receptor 8ImmunologyFemalemedicine.symptombusinessSignal Transduction
researchProduct